Brief: CEL-SCI Presents Phase 3 Data At ESMO 2022
12/09/2022 14:19
Sept 12 (Reuters) - CEL-SCI Corp CVM.A :
* CEL-SCI’S PHASE 3 DATA PRESENTED AT ESMO 2022: NEOADJUVANT
MULTIKINE ACHIEVED GROUNDBREAKING TUMOR RESPONSE & EXTENDED
OVERALL SURVIVAL IN LOCALLY ADVANCED HEAD AND NECK CANCER
Source text for Eikon: ID:nBw9Qd1Wma
Further company coverage: CVM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CEL-SCI
See all newsBrief: CEL-SCI Announces Closing Of Offering
Brief: Cel-Sci Corp Files For Offering Of 6 Million Shares Of Common Stock- SEC Filing
Brief: Cel-Sci Corporation Announces Pricing Of Public Offering
Brief: CEL-SCI Enters Strategic Agreement With Amarox For The Registration, Commercialization, And Distribution Of Multikine In Saudi Arabia
Drug developer CEL-SCI dives on deep-discounted equity raise